Can a Four-Drug cocktail tame a deadly lung complication of myositis?

This trial tests whether a combination of four immunosuppressant medications can improve survival in people with myositis who develop rapidly progressing interstitial lung disease (RP-ILD), a serious condition with a high early mortality rate. The study will enroll 80 adults with this condition and treat them with a 6-month regimen of steroids, rituximab, tacrolimus, and tofacitinib. The main goal is to see if this approach reduces the risk of death within the first six months of treatment.